ArticleEndocrine, metabolic & immune disorders drug targets2026
Andrographolide Attenuates Sepsis-Induced Acute Lung Injury
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSepsis-induced acute lung injury (ALI) is a life-threatening complication marked by intense inflammation, oxidative stress, and respiratory failure, with no effective targeted treatments available. This study aims to explore the protective effects of andrographolide (AGL) against sepsis-induced ALI and uncover its underlying mechanisms, focusing on the modulation of peroxisome proliferator-activated receptor gamma (PPARγ) as a potential therapeutic pathway.
methodsA murine model of ALI was established using cecal ligation and puncture (CLP). AGL was administered to evaluate its effects on pulmonary inflammation and oxidative stress. Neutrophil and macrophage infiltration, pulmonary edema, and levels of malondialdehyde and nitrite were measured in bronchoalveolar lavage (BAL) fluid and lung tissue, along with the expression of PPARγ and the activities of antioxidant enzymes superoxide dismutase (SOD) and catalase. The involvement of PPARγ was further confirmed using GW9662, a selective PPARγ antagonist.
resultsAGL treatment significantly attenuated neutrophil and macrophage infiltration, reduced pulmonary edema and inflammation, and decreased nitrite levels in BAL. Additionally, AGL upregulated PPARγ expression and enhanced SOD and catalase activity. These protective effects were significantly reversed by co-administration of GW9662, indicating a PPARγ-dependent mechanism. DISCUSSION: The present study demonstrated that AGL exerts significant protective effects against CLP-induced ALI, primarily through modulation of inflammatory and oxidative pathways.
conclusionAGL's ability to upregulate PPARγ and enhance SOD and catalase activity further supports its mechanistic role in mitigating lung damage. The reversal of AGL protective effects by GW9662 confirms its PPARγ-dependent mechanism, highlighting its potential as a targeted protective treatment for sepsis-induced ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.